structure-based drug design


Also found in: Acronyms.

structure-based drug design

The construction of candidate drugs after an analysis of the chemical structures of the receptors or targets to which they need to bind.
References in periodicals archive ?
Due to the overwhelmingly popularity of the Structure-Based Drug Design event, CHI will once again co-locate its Next-Gen Kinase Inhibitors conference to run June 17-19.
About Emerald BioStructures' Structure-based Drug Design
The company operates a high-throughput platform leveraged for fragment-based lead discovery and structure-based drug design.
This presentation will focus on radezolid, an oxazolidinone that was discovered using our proprietary structure-based drug design approach.
The easily downloadable LeadIT was released in January 2010, its empowering mix of established structure-based drug design and the latest fragment based lead discovery methods is already in widespread use by many pharma and biotech companies.
Emerald BioStructures (formerly deCODE biostructures) announced today a publication in the December 27, 2009 advance online issue of Nature Biotechnology, detailing the application of structure-based drug design (SBDD) to engineer new allosteric small molecule modulators of the enzyme phosphodiesterase-4 (PDE4), with reduced side effects.
These predicted three-dimensional structures are essential for structure-based drug design when experimental data are unavailable.
CytRx was awarded the grant by the National Institute of Diabetes and Digestive and Kidney Diseases, a part of the National Institutes of Heath (NIH), based on the Company's small molecule and structure-based drug design expertise.
The toolkit of technologies aimed at addressing the major challenges in drug discovery for protein-protein interactions encompasses structure-based drug design, peptide-based technologies, combinatorial and medicinal chemistry, fragment-based screening, and whole-pathway cellular assays.
He most recently served as Vice President of Drug Discovery at Celgene Corporation, where he managed screening, medicinal chemistry, structure-based drug design, PK/ADME and in vivo pharmacology.
Full browser ?